The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: A randomized, glucose clamp, crossover study

Diabetes Technology and Therapeutics

Volumn 10, Issue 6, 2008, Pages 479-485

  Heise, T ^a   Eckers, U ^a   Kanc, K ^b   Nielsen, J N ^b   Nosek, L ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; BIPHASIC INSULIN ASPART; FATTY ACID; GLUCOSE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; INFUSION RATE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 57349134684     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0019     Document Type: Article

References (31)

1. Bolli GB: Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S317-332.
2. Brange J, Volund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-335.
3. Bretzel RG, Arnolds S, Medding J, Linn T: A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004;27:1023-1027.
4. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group: Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-770.
5. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999;22:801-805.
6. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S: Improved postprandial glycemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000;37:41-46.
7. 1c. Diabetes Care 2003;26:881-885.
8. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
9. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
10. Home P: Contributions of basal and post-prandial hyperglycemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005;21:989-998.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
13. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA: Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622-629.
14. Weyer C, Heinemann L, Heise T: Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997;20:1612-1614.
15. Jacobsen LV, Søgaard B, Riis A: Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403.
16. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L: Reduced postprandial glycemic exursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet Med 2004;21:500-501.
17. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R: Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study). Diabetes Obes Metab 2006;8:58-66.
18. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; the 4T Study Group: Addition of biphasic, prandial, or basal insulin therapy to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
19. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L: Different premixed formulations of biphasic insulin aspart show clear differentiations in onset and duration of action. [abstract P50]. Diabet Med 2007;24(Suppl 1):44.
20. Eckers U, Heise T, Kanc K, Nielsen JN, Nosek L: Clear differentiations in onset and duration of action are shown with different premixed ratios of biphasic insulin aspart (BIAsp) [abstract]. Diabetologia 2007;50(Suppl 1):S397.
21. Allison P: Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Publishing, 1995.
22. Charbonnel B, Balarac N, Cazeneuve B, Augendre-Ferrante B, Le Thai F, Drouin P: Which are the insulin treatment regimens used in France. Diabetes Metab 2001;27:591-597.
23. Heise T, Kapitza C, Jacobsen LV, Brøndsted L, Heinemann L: Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70 [abstract]. Diabetologia 2005;48(Suppl 1):A301.
24. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
25. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG: Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452.
26. Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T: Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. Clin Ther 2007;29:927-934.
27. Bott S, Tusek C, Heinemann L, Friberg HH, Heise T: The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30). Exp Clin Endocrinol Diabetes 2005;113:545-550.
28. Chen JW, Lauritzen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS: Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes. A randomized double-blinded crossover study. Diabet Med 2005;22:273-277.
29. Kabadi UM, Kabadi M: Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract 2006;72:265-270.
30. Clements M, Tits B, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ: Improved glycemic control of thrice daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008;10:229-237.
31. Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, Le Devehat C, Romero E, Liebl A: Biphasic insulin aspart given thrice daily is as efficacious as a conventional basal-bolus insulin regimen with four daily injections; a randomized open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:511-519.